Do glucocorticoid (steroid) therapy require Pneumocystis jirovecii pneumonia (PCP) prophylaxis when used alone, or only when combined with another immunosuppressive agent?

PCP Prophylaxis with Steroids: Monotherapy vs Combination Therapy

Steroids alone at high doses (>15-30 mg prednisone equivalent daily for >2-4 weeks) warrant PCP prophylaxis, though the risk substantially increases when combined with other immunosuppressants. 1

Primary Recommendation

Based on the 2022 EULAR guidelines, prophylaxis against Pneumocystis jirovecii pneumonia should be considered in patients receiving high-dose glucocorticoids, with particular emphasis when combined with immunosuppressants. 1 The evidence demonstrates that steroids alone can necessitate prophylaxis, but combination therapy significantly amplifies risk.

Steroid Monotherapy Thresholds

The guidelines indicate prophylaxis is beneficial when:

• Daily doses exceed 15-30 mg prednisolone equivalent
• Duration extends beyond 2-4 weeks 1

However, real-world data challenges these thresholds. A 2024 Canadian study found that 48.8% of PCP cases would not have qualified for prophylaxis under current guidelines, including 22 patients on steroids for <28 days and 2 patients on <20 mg/day prednisone equivalent. 2 This suggests current thresholds may be insufficient.

Combination Therapy: Substantially Higher Risk

When glucocorticoids are combined with other immunosuppressants, the risk of PCP increases 2.85-fold compared to steroid monotherapy (95% CI 1.75-4.64), with worse prognoses (OR 2.31 for poor outcomes). 3 The EULAR guidelines explicitly note that coadministration of immunosuppressants with glucocorticoids increases PCP risk. 1

Additional Risk Factors to Consider

Beyond medication regimen, assess for:

• Persistent lymphopenia (strong predictor) 1, 4
• Older age 1
• Pre-existing lung disease 1
• Underlying autoimmune inflammatory disease type (particularly granulomatosis with polyangiitis) 4

A 2015 study demonstrated that high-dose glucocorticoid (≥30 mg prednisolone daily) carried a relative risk of 19 for PCP development (95% CI 2.0-182.8), with 50% in-hospital mortality in those who developed PCP. 5

Prophylaxis Regimen

First-line: Trimethoprim-sulfamethoxazole (TMP-SMX)

• 480 mg daily (single-strength) OR
• 960 mg three times weekly 1
• Half-strength daily dosing may reduce adverse events while maintaining efficacy 1

Common adverse events (affecting ~20% of patients): nausea, headache, rash 1

Special caution: Higher adverse event rates with methotrexate (cytopenia risk) and in systemic lupus erythematosus patients 1

Alternatives when TMP-SMX not tolerated:

• Atovaquone
• Dapsone
• Nebulized pentamidine 1

These alternatives appear equally effective but are limited by cost or administration requirements. 1

Clinical Reality vs Guidelines

Critical pitfall: Current prophylaxis practices are inadequate. A 2024 study showed only 4.7% of PCP patients received prophylaxis, and 83.7% were on corticosteroids prior to diagnosis. 2 A 2025 US study found prophylaxis rates were low overall, with paradoxically lower prophylaxis odds at higher glucocorticoid doses. 6

Practical Algorithm

Initiate PCP prophylaxis if ANY of the following:

1. Prednisone ≥20 mg daily for ≥2-4 weeks (monotherapy)
2. Prednisone ≥15 mg daily PLUS any other immunosuppressant
3. Any dose steroids PLUS lymphopenia (<1000 cells/μL)
4. Any dose steroids PLUS pre-existing lung disease PLUS age >60
5. Granulomatosis with polyangiitis on any immunosuppression 4

Consider prophylaxis even at lower thresholds given the 50% mortality rate when PCP develops and the evidence that nearly half of cases fall outside traditional criteria. 2, 5